Should the recommendation of the american association of clinical endocrinologists for a hemoglobin a1c target of 6.5% be modified? A critical reappraisal of recent studies of intensive glycemic control

Endocrine Practice

Volumn 14, Issue 6, 2008, Pages 791-795

  Rodbard, Helena W ^a   Trence, Dace L ^b   Mechanick, Jeffrey I ^c  

^a Endocrine and Metabolic Consultants   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; GLYCOSYLATED HEMOGLOBIN;

DISEASE DURATION; EVIDENCE BASED MEDICINE; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; MEDICAL SOCIETY; NOTE; PRACTICE GUIDELINE; ARTICLE; BLOOD; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL;

BLOOD GLUCOSE; DIABETES MELLITUS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 64749091354     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.14.6.791     Document Type: Note

References (33)

1. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13(suppl 1):1-68.
2. AACE Ad Hoc Task Force for Standardized Production of Clinical Practice Guidelines. American Association of Clinical Endocrinologists protocol for standardized production of clinical practice guidelines. Endocr Pract. 2004;10:353-361.
3. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
4. Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy [published correction appears in N Engl J Med. 2000;342:1376]. N Engl J Med. 2000;342:381-389.
5. Nathan DM, Cleary PA, Backlund JY, et al (Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications [DCCT/ EDIC] Study Research Group). Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-2653.
6. Nathan DM, Lachin J, Cleary P, et al (Diabetes Control and Complications Trial; Epidemiology of Diabetes Interventions and Complications Research Group). Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med. 2003;348:2294-2303.
7. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in Lancet. 1999;354:602]. Lancet. 1998;352:837-853.
8. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-412.
9. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Longterm results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000;23(suppl 2):B21-B29.
10. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-393.
11. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580-591.
12. Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycemia in type 2 diabetes. Diabet Med. 2008;25:245-254.
13. Nesto RW, Bell D, Bonow RO, et al (American Heart Association; American Diabetes Association). Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation. 2003;108:2941-2948.
14. Fonseca V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med. 2003;115(suppl 8A):42S-48S.
15. Abraira C, Moritz TE, Reaven P, Duckworth WC, Fonseca V. Glycemic control and cardiovascular outcomes - the VA Diabetes Trial. Presented at: 68th Annual Scientific Sessions of the American Diabetes Association; June 8, 2008; San Francisco, CA. http://www.diabetesconnect.org/storetemplate/Webcast-list. aspx?ses=874. Accessed for verification August 18, 2008.
16. Gerstein HC, Miller ME, Byington RP, et al (Action to Control Cardiovascular Risk in Diabetes Study Group). Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-2559.
17. Patel A, MacMahon S, Chalmers J, et al (ADVANCE Collaborative Group). Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572.
18. Meyers CD, McCarren M, Wong ND, Abraira C, Duckworth WC, Kashyap ML (VADT Investigators). Baseline achievement of lipid goals and usage of lipid medications in patients with diabetes mellitus (from the Veterans Affairs Diabetes Trial). Am J Cardiol. 2006;98:63-65.
19. Duckworth WC, McCarren M, Abraira C (VADT Investigators). Control of cardiovascular risk factors in the Veterans Affairs Diabetes Trial in advanced type 2 diabetes. Endocr Pract. 2006;12(suppl 1):85-88.
20. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes [published correction appears in N Engl J Med. 2007;357:100]. N Engl J Med. 2007;356:2457-2471.
21. Weber KK, Lohmann T, Busch K, Donati-Hirsch I, Riel R. High frequency of unrecognized hypoglycaemias in patients with type 2 diabetes is discovered by continuous glucose monitoring. Exp Clin Endocrinol Diabetes. 2007;115:491-494.
22. Guerci B, Floriot M, Böhme P, et al. Clinical performance of CGMS in type 1 diabetic patients treated by continuous subcutaneous insulin infusion using insulin analogs. Diabetes Care. 2003;26:582-589.
23. McNally PG, Dean JD, Morris AD, Wilkinson PD, Compion G, Heller SR. Using continuous glucose monitoring to measure the frequency of low glucose values when using biphasic insulin aspart 30 compared with biphasic human insulin 30: a double-blind crossover study in individuals with type 2 diabetes. Diabetes Care. 2007;30:1044-1048.
24. Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med. 2008;358:2630-2633.
25. Cefalu WT. Glycemic targets and cardiovascular disease. N Engl J Med. 2008;358:2633-2635.
26. Kim NH, Pavkov ME, Looker HC, et al. Plasma glucose regulation and mortality in Pima Indians. Diabetes Care. 2008;31:488-492.
27. Rosengren A, Wedel H, Wilhelmsen L. Body weight and weight gain during adult life in men in relation to coronary heart disease and mortality: a prospective population study. Eur Heart J. 1999;20:269-277.
28. Norhammar A, Tenerz A, Nilsson G, et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet. 2002;359:2140-2144.
29. Beals JK. VA Diabetes Trial shows that intensive glucose control has little effect on cardiovascular risk. http://www.theHeart.org/article/ 875871.do. Accessed for verification August 18, 2008.
30. Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet. 2008;371:1753-1760.
31. Milicevic Z, Raz I, Strojek K, et al (HEART2D Study). Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus (HEART2D) Study design. J Diabetes Complications. 2005;19:80-87.
32. Gerstein H, Yusef S, Riddle MC, Ryden L, Bosch J (ORIGIN Trial Investigators). Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction With an Initial Glargine Intervention). Am Heart J. 2008;155:26-32.
33. Magee MF, Isley W (BARI 2D Trial Investigators). Rationale, design, and methods for glycemic control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Am J Cardiol. 2006;97:20G-30G.